DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the ORCHID PHARMA LIMITED (ORCHPHARMA) share price today?

ORCHID PHARMA LIMITED (ORCHPHARMA) is trading at ₹1,041.35 on the NSE, down 3.48% on the day. Source: DocStoX.

What is the PE ratio of ORCHID PHARMA LIMITED?

ORCHID PHARMA LIMITED has a price-to-earnings (PE) ratio of 257.1 in the Healthcare sector.

What is the market capitalisation of ORCHID PHARMA LIMITED?

ORCHID PHARMA LIMITED has a market capitalisation of approximately ₹5,259 crore.

ORCHID PHARMA LIMITED

ORCHPHARMA·NSE·Healthcare

₹1,041.35▼ -37.60 (-3.48%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹1027.10

₹1084.30

52W₹480

₹112088%

Open

₹1084.30

High

₹1084.30

Low

₹1027.10

Prev Close

₹1078.95

Volume

1.22L

VWAP

₹1051.82

Snapshot

Key fundamentals

Market Cap

₹5,259 Cr

P/E Ratio

257.12Expensive

P/B Ratio

3.86

EPS

₹4.05

Book Value

₹254.00

ROE

2.12%Weak

ROCE

3.00%Weak

Dividend Yield

0.00%

Debt / Equity

0.28Low

Face Value

₹10.00

52W High

₹1119.80

52W Low

₹480.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatMedium uncertainty

Fair value estimate

₹208

▼ 80.1%downside

Trading at ₹1,041 — 80% above our estimate

BearFair valueBull

₹152₹208₹239

/100

Business quality — Watch the fundamentals

Growth 14Profitability 2Efficiency 0Valuation 43

Plain English

Our view

A steady, established business
Low debt relative to equity
Weak returns on equity (2%)

Strengths

Low debt relative to equity
Promoters hold a controlling stake

Risks

Weak returns on equity (2%)
Expensive — trades at 257× earnings
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

2% ROE fading to 12% over ~3 yrs, on ₹254 book

₹223

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹152

Analyst target

No analyst coverage

—

Blended fair value₹208

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Promoters hold a controlling stake

Bear case

Weak returns on equity (2%)
Expensive — trades at 257× earnings
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

257.1Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

2.1%Weak

Above 15% is considered healthy for Indian equities

ROCE

3.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.28Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹5,259 Cr

P/B

3.86

EPS

₹4.05

Div Yield

—

What changed

Recent changes

Foreign investors-0.3% stake last quarter
Domestic institutions+0.9% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 257.1×

Growth

Steady

+7% rev CAGR

Profitability

Modest

2.1% ROE

Financial health

Rock solid

D/E 0.28

Momentum

N/A

No technicals

Today

Trading activity

Delivery %40.4%

Turnover₹1285.57L Cr

Trades10,839

VWAP₹1051.82

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+6.8%

+12.5%

10Y

-0.7%

Profit

-23.0%

—

10Y

—

EPS

-29.1%

—

10Y

—

Profile

Cons

Stock is trading at 3.99 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
Tax rate seems low
Company has a low return on equity of 6.41% over last 3 years.
Company might be capitalizing the interest cost
Earnings include an other income of Rs.28.6 Cr.
Promoter holding has decreased over last 3 years: -20.1%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 0.30 pts; domestic institutions added 0.86 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

70%

Promoter

Promoters

69.8%0.00

Public

6.6%-0.18

FII / FPI

0.9%-0.30

DII

20.3%+0.86

Others

2.5%

Total shareholders

35,118-591 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter69.84%

FII0.87%

DII20.25%

Public6.58%

Others2.46%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions